Enzyme Catalysis in Organic Synthesis 2002
DOI: 10.1002/9783527618262.ch16e
|View full text |Cite
|
Sign up to set email alerts
|

Baeyer‐Villiger Oxidations

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2004
2004
2020
2020

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 23 publications
(2 citation statements)
references
References 127 publications
0
2
0
Order By: Relevance
“…BVMOs, in particular CHMO, are versatile biocatalysts that have been widely used in synthetic biotransformations. They contain a flavin moiety as the prosthetic group and utilize NAD(P)H as a stoichiometric cofactor (see Figure ). In view of the requirement for cofactor regeneration, these reactions are generally performed with whole microbial cells in a fermentation mode.…”
Section: 22 Bvmosmentioning
confidence: 99%
“…BVMOs, in particular CHMO, are versatile biocatalysts that have been widely used in synthetic biotransformations. They contain a flavin moiety as the prosthetic group and utilize NAD(P)H as a stoichiometric cofactor (see Figure ). In view of the requirement for cofactor regeneration, these reactions are generally performed with whole microbial cells in a fermentation mode.…”
Section: 22 Bvmosmentioning
confidence: 99%
“…The microbial Baeyer−Villiger oxidation (Scheme ) has received substantial attention in recent years as a valuable tool for the transformation of prochiral or racemic ketones into optically pure lactones which are attractive intermediates in organic synthesis. Thanks to progress in genome deciphering during the past years, an increasing diversity of Baeyer−Villiger monooxygenases (BVMOs) has become available as versatile catalysts for such stereoselective transformations which fulfill the requirements of sustainable and green chemistry strategies . Until recently, widespread application of such catalytic entities was limited by a general obstacle of biocatalysis: While access to both antipodal forms of a product can be achieved with de novo designed synthetic catalysts, no generally applicable strategy is available to provide enantiocomplementarity in biocatalysis.…”
mentioning
confidence: 99%